Shots:
- Biocon Biologics has expanded its strategic collaboration with Civica to commercialize Insulin Glargine in the US
- Biocon Biologics & Civica entered into a multi-year exclusive distributorship where Biocon will manufacture & supply Insulin Glargine, & Civica will handle its commercialization in the US under its own label, incl. the CalRx brand in California
- No technology transfer is involved, & Biocon Biologics will retain IP, marketing rights, & will continue to directly commercialize its FDA-approved interchangeable biosimilar Insulin Glargine-yfgn
Ref: PRNewsWire | Image: Biocon Biologics & Civica | Press Release
Related News:- Biocon Biologics Partners with Civica to extend access of Insulin Aspart in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
